secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001213900-21-051257
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helix Acquisition Corp. announces business combination with MoonLake Immunotherapeutics; $115M PIPE
--------------------------------------------------------------------------------

- Helix (HLXA) to combine with MoonLake Immunotherapeutics AG, a Swiss immuno-dermatology biotech.
- PIPE of $115M at $10.00/share from investors including sponsor affiliate and existing MoonLake holders.
- Combined company to rename as MoonLake Immunotherapeutics; Helix Class B shares convert to Class A 1:1.
- Closing expected late Q4 2021/early Q1 2022, subject to shareholder approvals and minimum $150M cash condition.
- Post-closing board: 7 directors (4 designated by MoonLake, 2 by Helix, plus Jorge Santos da Silva).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/0001213900-21-051257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872-8k_helixacq.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-051257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer